Literature DB >> 26255027

The role of microenvironment and immunity in drug response in leukemia.

Emyr Bakker1, Malak Qattan2, Luciano Mutti1, Constantinos Demonacos3, Marija Krstic-Demonacos4.   

Abstract

Leukemia is a cancer of the white blood cells, with over 54,000 new cases per year diagnosed worldwide and a 5-year survival rate below 60%. This highlights a need for research into the mechanisms behind its etiology and causes of therapy failure. The bone marrow microenvironment, in which adult stem cells are maintained in healthy individuals, has been implicated as a source of chemoresistance and disease relapse. Here the various ways that the microenvironment can contribute to the resistance and persistence of leukemia are discussed. The targeting of the microenvironment by leukemia cells to create an environment more suitable for cancer progression is described. The role of soluble factors, drug transporters, microvesicles, as well as the importance of direct cell-cell contact, in addition to the effects of inflammation and immune surveillance in microenvironment-mediated drug resistance are discussed. An overview of the clinical potential of translating research findings to patients is also provided. Understanding of and further research into the role of the bone marrow microenvironment in leukemia progression and relapse are crucial towards developing more effective treatments and reduction in patient morbidity. This article is part of a Special Issue entitled: Tumor Microenvironment Regulation of Cancer Cell Survival, Metastasis, Inflammation, and Immune Surveillance edited by Peter Ruvolo and Gregg L. Semenza. Crown
Copyright © 2015. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer; Immune surveillance; Inflammation; Leukemia; Microenvironment; Novel therapeutics

Mesh:

Substances:

Year:  2015        PMID: 26255027     DOI: 10.1016/j.bbamcr.2015.08.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  25 in total

1.  Combination Therapy for Treating Advanced Drug-Resistant Acute Lymphoblastic Leukemia.

Authors:  Yorleny Vicioso; Hermann Gram; Rose Beck; Abhishek Asthana; Keman Zhang; Derek P Wong; John Letterio; Reshmi Parameswaran
Journal:  Cancer Immunol Res       Date:  2019-05-28       Impact factor: 11.151

Review 2.  Immunomodulation in leukemia: cellular aspects of anti-leukemic properties.

Authors:  M Maleknia; A Valizadeh; S M S Pezeshki; N Saki
Journal:  Clin Transl Oncol       Date:  2019-05-24       Impact factor: 3.405

Review 3.  Screening out irrelevant cell-based models of disease.

Authors:  Peter Horvath; Nathalie Aulner; Marc Bickle; Anthony M Davies; Elaine Del Nery; Daniel Ebner; Maria C Montoya; Päivi Östling; Vilja Pietiäinen; Leo S Price; Spencer L Shorte; Gerardo Turcatti; Carina von Schantz; Neil O Carragher
Journal:  Nat Rev Drug Discov       Date:  2016-09-12       Impact factor: 84.694

4.  Cyclophosphamide Enhances Cancer Antibody Immunotherapy in the Resistant Bone Marrow Niche by Modulating Macrophage FcγR Expression.

Authors:  Ali Roghanian; Guangan Hu; Christopher Fraser; Maneesh Singh; Russell B Foxall; Matthew J Meyer; Emma Lees; Heather Huet; Martin J Glennie; Stephen A Beers; Sean H Lim; Margaret Ashton-Key; Stephen M Thirdborough; Mark S Cragg; Jianzhu Chen
Journal:  Cancer Immunol Res       Date:  2019-08-26       Impact factor: 11.151

5.  Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL.

Authors:  Luke Jones; Jennifer Richmond; Kathryn Evans; Hernan Carol; Duohui Jing; Raushan T Kurmasheva; Catherine A Billups; Peter J Houghton; Malcolm A Smith; Richard B Lock
Journal:  Clin Cancer Res       Date:  2017-01-24       Impact factor: 12.531

Review 6.  Anti-Cancer Drug Validation: the Contribution of Tissue Engineered Models.

Authors:  Mariana R Carvalho; Daniela Lima; Rui L Reis; Joaquim M Oliveira; Vitor M Correlo
Journal:  Stem Cell Rev Rep       Date:  2017-06       Impact factor: 5.739

7.  CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk.

Authors:  Constance Baer; Shunsuke Kimura; Mitra S Rana; Andrew B Kleist; Tim Flerlage; David J Feith; Peter Chockley; Wencke Walter; Manja Meggendorfer; Thomas L Olson; HeeJin Cheon; Kristine C Olson; Aakrosh Ratan; Martha-Lena Mueller; James M Foran; Laura J Janke; Chunxu Qu; Shaina N Porter; Shondra M Pruett-Miller; Ravi C Kalathur; Claudia Haferlach; Wolfgang Kern; Elisabeth Paietta; Paul G Thomas; M Madan Babu; Thomas P Loughran; Ilaria Iacobucci; Torsten Haferlach; Charles G Mullighan
Journal:  Nat Genet       Date:  2022-05-05       Impact factor: 41.307

8.  Combinatorial Efficacy of Quercitin and Nanoliposomal Ceramide for Acute Myeloid Leukemia.

Authors:  Colin M McGill; Timothy J Brown; Lindsey N Fisher; Sally J Gustafson; Kriya L Dunlap; Adam J Beck; Paul T Toran; David F Claxton; Brian M Barth
Journal:  Int J Biopharm Sci       Date:  2018-01-31

Review 9.  The Regulation of Pathways of Inflammation and Resolution in Immune Cells and Cancer Stem Cells by Selenium.

Authors:  Bastihalli T Diwakar; Arvind M Korwar; Robert F Paulson; K Sandeep Prabhu
Journal:  Adv Cancer Res       Date:  2017-08-31       Impact factor: 6.242

Review 10.  Modulation of the tumor microenvironment by natural agents: implications for cancer prevention and therapy.

Authors:  Haseeb Zubair; Mohammad Aslam Khan; Shashi Anand; Sanjeev Kumar Srivastava; Seema Singh; Ajay Pratap Singh
Journal:  Semin Cancer Biol       Date:  2020-05-26       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.